

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2768547
<b>Application Number:</b>	10802220
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3562
<b>Title of Invention:</b>	Pharmaceutical compositions of CETP inhibitors
<b>First Named Inventor/Applicant Name:</b>	Masaki Sunami
<b>Customer Number:</b>	23460
<b>Filer:</b>	John Jr. Kilyk/Loraine Perry
<b>Filer Authorized By:</b>	John Jr. Kilyk
<b>Attorney Docket Number:</b>	227833
<b>Receipt Date:</b>	25-JAN-2008
<b>Filing Date:</b>	17-MAR-2004
<b>Time Stamp:</b>	15:20:34
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Fee Worksheet (PTO-06)	ROATransmittal.pdf	57451 <small>0b5ebd65a8485175b21c4653b1c5b4c 612aa3a399</small>	no	1

**Warnings:**

**Information:**

2	Amendment - After Non-Final Rejection	ROA.pdf	2096657 7f314843ff18d4c3ecdd7b76c5886c40a56a295f1	no	31
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Antonova-Comptesrendus-1993.pdf	981654 d197c4becd990320080748f62bc7c3c1d3bc0533	no	4
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Connolly-BiochemBiophysResComm-1996.pdf	484602 5b8f7d966c7b23a2c9f54b40f3744587337457b4	no	8
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	DeGrowth-Circulation-2001.pdf	339226 17559e563053c6f3e27b3856231b1b67587b5034	no	3
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	DeGrowth-XIVIntSymp-2001.pdf	199015 e387d4e9094e13689812a44ad71c987b304ad797	no	2
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Drozdz-ZhurnalOrganicheskoiKhimii-1987.pdf	979739 93dd871b91a615d4192e31913d13ba2e0304b	no	10
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Egan-AdvProstaglandinThromboxaneLeukotrienResearch-1983.pdf	414355 884f2644996c72956fd3d5c5cc85ed076d17b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Hori-Heterocycles-1978.pdf	923272 69b3da7447c36349995a232a5a35e3be9e04027	no	6
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Huang-ClinicalScience-2002.pdf	614184 f709b80ec5e58c4938714d433a396e2b32e5683a	no	8
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	Watts-ClinicalScience-2002.pdf	128518 114e2eb6e2ae015d518dac4684683d0d66d3b01	no	2
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Maeda-BioorganicMedicinalChemLtrs-2004.pdf	372476 d3c7d1f5dee67a3e79581835145d6803a1c31ea0214	no	5
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Nagarajan-IndianJofChem-1974.pdf	1001605 29e93d906a2f615a557b7061c3c1d3a1501a67b936	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Okamoto-BIOClinica-2003.pdf	262248 39b031fa696397e4a00720d9a7ebd0aee03379da	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Okamoto-EPJofPharmacology-2003.pdf	852956 6a831a82a530e99a17b06fc338e762a3ee658ec	no	8
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Okamoto-Lipid-2002.pdf	336900 26c7e9771399df566d3775f8ba0a396a750b405	no	7
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Shimoji-Atherosclerosis-2004.pdf	1015530 0d6b6661ea8304e3c505073211a4c8f09925ea67	no	11
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Shinkai-NaibunpiTonyobyok-a-2001.pdf	1085927 53b34dbf792d53bc9edfa79973b7137e40e729e41	no	8
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Simov-KhimiyaGeterotsiklicheskikhSoedinenii-1976.pdf	254592 0bb14f076f10d3017c96e0a90ee0392d00e9c	no	5
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	Wakitani-KnowledgeFoundations2ndIntConfonHDL-2001.pdf	597008 actb56453d82a645c8c50a73c4be995a bd4a1546	no	5
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	WCNWorkingGroup-SlidePresentedatWCNMeeting-2002.pdf	605371 796add85c279d95d42180300b5811520c 5ab70327	no	1
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			13603286		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>					
<p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>					
<p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					
<p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					